SCHEDULE: Indaptus Therapeutics SEC Filing: No Beneficial Ownership Reported

Multiple entities and individuals associated with Yorkville Advisors have filed a Schedule 13G amendment for Indaptus Therapeutics, reporting zero shares beneficially owned.

Summary

• This filing is an amendment to a Schedule 13G for Indaptus Therapeutics, Inc.
• Several reporting persons, including YA II PN, Ltd., YA Global Investments II (U.S.), LP, Yorkville Advisors Global, LP, Yorkville Advisors Global II, LLC, YAII GP, LP, YAII GP II, LLC, Mark Angelo, and SC-Sigma Global Partners, LP, are listed.
• All reporting persons state they have 0 shares beneficially owned, 0 sole voting power, 0 shared voting power, 0 sole dispositive power, and 0 shared dispositive power.
• The filing indicates that each reporting person may be deemed an affiliate of each other reporting person, and that Mark Angelo makes investment decisions for YA II.
• The date of the event requiring the filing is December 31, 2025.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the complete absence of reported beneficial ownership by entities typically involved in significant investments, suggesting no current strategic stake.

Negatives

• All reporting entities and individuals declare zero beneficial ownership of Indaptus Therapeutics' common stock.
• This indicates no significant stake or control by these entities in the company as of the filing date.

Future Outlook

No forward-looking statements or guidance are present in this filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors who acquire beneficial ownership of more than 5% of a class of a company's registered equity securities. The absence of any reported beneficial ownership by these entities, particularly those associated with investment management firms, suggests a lack of significant current investment or a change in their holdings to below the reporting threshold.

Stakeholder Impact

• Shareholders: The filing provides no indication of significant ownership changes or new strategic stakes by these reporting entities, thus likely having minimal immediate impact on share price or investor sentiment.

Key Dates

Keywords

Indaptus Therapeutics, Schedule 13G, SEC Filing, Beneficial Ownership, Yorkville Advisors, YA II PN, Ltd., Investment Management